KR102738306B1 - Cxcr4 수용체 길항제 - Google Patents

Cxcr4 수용체 길항제 Download PDF

Info

Publication number
KR102738306B1
KR102738306B1 KR1020187019798A KR20187019798A KR102738306B1 KR 102738306 B1 KR102738306 B1 KR 102738306B1 KR 1020187019798 A KR1020187019798 A KR 1020187019798A KR 20187019798 A KR20187019798 A KR 20187019798A KR 102738306 B1 KR102738306 B1 KR 102738306B1
Authority
KR
South Korea
Prior art keywords
methyl
imidazo
pyrimidin
tetrahydroquinolin
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187019798A
Other languages
English (en)
Korean (ko)
Other versions
KR20180094036A (ko
Inventor
그레첸 엠. 슈뢰더
트램 엔. 현
하이디 엘. 페레즈
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20180094036A publication Critical patent/KR20180094036A/ko
Application granted granted Critical
Publication of KR102738306B1 publication Critical patent/KR102738306B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187019798A 2015-12-15 2016-12-14 Cxcr4 수용체 길항제 Active KR102738306B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267649P 2015-12-15 2015-12-15
US62/267,649 2015-12-15
PCT/US2016/066575 WO2017106291A1 (en) 2015-12-15 2016-12-14 Cxcr4 receptor antagonists

Publications (2)

Publication Number Publication Date
KR20180094036A KR20180094036A (ko) 2018-08-22
KR102738306B1 true KR102738306B1 (ko) 2024-12-03

Family

ID=57755467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187019798A Active KR102738306B1 (ko) 2015-12-15 2016-12-14 Cxcr4 수용체 길항제

Country Status (6)

Country Link
US (1) US10450318B2 (https=)
EP (1) EP3390406A1 (https=)
JP (1) JP6856648B2 (https=)
KR (1) KR102738306B1 (https=)
CN (1) CN108602829A (https=)
WO (1) WO2017106291A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
CN109553604B (zh) * 2017-09-25 2021-08-27 盛世泰科生物医药技术(苏州)有限公司 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511621A (ja) 2001-11-16 2005-04-28 アストラゼネカ・アクチエボラーグ ケモカインレセプターの調節物質としての新規ピペリジン誘導体
JP2008511669A (ja) 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
JP2008524255A (ja) 2004-12-17 2008-07-10 スミスクライン ビーチャム コーポレーション 化学物質
JP2009524690A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
PT1910370E (pt) 2005-07-22 2015-06-30 Lilly Co Eli Um pirrolo[1,2-b]pirazole mono-hidratado substituído com piridina e quinolina como inibidor do tgf-beta
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
CN103372215B (zh) 2008-01-03 2016-03-09 艾克斯-马赛大学 抗hiv治疗期间使用的组合物和方法
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511621A (ja) 2001-11-16 2005-04-28 アストラゼネカ・アクチエボラーグ ケモカインレセプターの調節物質としての新規ピペリジン誘導体
JP2008511669A (ja) 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
JP2008524255A (ja) 2004-12-17 2008-07-10 スミスクライン ビーチャム コーポレーション 化学物質
JP2009524690A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物

Also Published As

Publication number Publication date
JP6856648B2 (ja) 2021-04-07
US10450318B2 (en) 2019-10-22
CN108602829A (zh) 2018-09-28
EP3390406A1 (en) 2018-10-24
WO2017106291A1 (en) 2017-06-22
JP2019502680A (ja) 2019-01-31
US20180327409A1 (en) 2018-11-15
KR20180094036A (ko) 2018-08-22

Similar Documents

Publication Publication Date Title
JP6482629B2 (ja) Ｔｒｋａキナーゼ阻害剤としてのｎ−ピロリジニル、ｎ’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
KR102085121B1 (ko) 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
CN109476641B (zh) Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
JP6836998B2 (ja) ＴＧＦ−β阻害剤
CA2961740C (en) N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors
US9708316B2 (en) TGFβR antagonists
JP7254821B2 (ja) 抗がん剤としての環状ジヌクレオチド
JP6843767B2 (ja) 抗がん剤としての三環式化合物
KR20250113487A (ko) 화합물
JP2019516759A (ja) がんの処置のためのピラゾロピリジン誘導体
EA038071B1 (ru) СОЕДИНЕНИЕ СПИРО[3H-ИНДОЛ-3,2'-ПИРРОЛИДИН]-2(1H)-ОНА И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MDM2-p53
CN115443276A (zh) 吡啶并嘧啶酮衍生物及其作为芳烃受体调节剂的应用
US20230339891A1 (en) Uracil derivatives as mer-axl inhibitors
KR102738306B1 (ko) Cxcr4 수용체 길항제
EP4051388A1 (en) Substituted pyrazole compounds as toll receptor inhibitors
JP2018528951A (ja) ＴＧＦβ受容体アンタゴニスト
JP2018525415A (ja) Ｔｇｆベータ受容体アンタゴニスト
US10399987B2 (en) TGF beta receptor antagonists
US20190337942A1 (en) Tgf beta receptor antagonists
US20240109899A1 (en) Benzofuran compounds as sting agonists
CN120513245A (zh) 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180711

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211206

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240902

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241129

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241129

End annual number: 3

Start annual number: 1

PG1601 Publication of registration